RE:RE:RE:RE:RE:RE:Brokered Private PlacementI think where Shiseido would run into problems with that argument is that in the original contract stipulated that Replicel would share its RCH-01 patented information which formed the basis of Shiseido's first Trial and most likely the second Trial as well. They may claim it is different technology but I think the Arbitrator will not agree with them in this regard. Also where Shiseido is in breach is that they have never shared any findings from their first Trial with Replicel and the Contract stated that any and all collaboration must be shared between the companies.